Establishing a Non-invasive Diagnostic Biomarker Test for Early Diagnosis of Lung Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lungcancer
- Sponsor
- University Hospital, Essen
- Enrollment
- 70
- Locations
- 1
- Primary Endpoint
- DNA Methylation at early stages of lung cancer
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis.
In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included.
SHOX2 and PTGER4 will be analyzed via PCR.
Detailed Description
Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis. In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included. A total of 150 patients will be enrolled in this study. SHOX2 and PTGER4 will be analyzed via PCR of blood plasma samples.
Investigators
Kaid Darwiche
Priv.-Doz. Dr. med. Kaid Darwiche, head of department of interventional pneumology
University Hospital, Essen
Eligibility Criteria
Inclusion Criteria
- •suspicious finding for lung cancer on CT-scan
Exclusion Criteria
- •history significant for former malignant diseases
Outcomes
Primary Outcomes
DNA Methylation at early stages of lung cancer
Time Frame: 1 year